Market closedNon-fractional
Lyell Immunopharma/LYEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Lyell Immunopharma
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Ticker
LYEL
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South San Francisco, United States
Employees
224
Website
lyell.com
LYEL Metrics
BasicAdvanced
$416M
Market cap
-
P/E ratio
-$0.91
EPS
-0.40
Beta
-
Dividend rate
Price and volume
Market cap
$416M
Beta
-0.4
Financial strength
Current ratio
16.511
Quick ratio
16.267
Long term debt to equity
9.145
Total debt to equity
10.25
Management effectiveness
Return on assets (TTM)
-18.93%
Return on equity (TTM)
-32.93%
Valuation
Price to revenue (TTM)
6,059.48
Price to book
0.69
Price to tangible book (TTM)
0.69
Price to free cash flow (TTM)
-2.558
Growth
Revenue change (TTM)
-99.92%
Earnings per share change (TTM)
23.66%
3-year revenue growth (CAGR)
-80.34%
3-year earnings per share growth (CAGR)
-61.37%
What the Analysts think about LYEL
Analyst Ratings
Majority rating from 4 analysts.
LYEL Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$61M
14.56%
Profit margin
0.00%
NaN%
LYEL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.26
-$0.20
-$0.20
-$0.24
-
Expected
-$0.27
-$0.25
-$0.23
-$0.21
-$0.19
Surprise
-4.88%
-20.00%
-12.28%
14.29%
-
LYEL News
AllArticlesVideos
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
GlobeNewsWire·1 month ago
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
GlobeNewsWire·2 months ago
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lyell Immunopharma stock?
Lyell Immunopharma (LYEL) has a market cap of $416M as of July 27, 2024.
What is the P/E ratio for Lyell Immunopharma stock?
The price to earnings (P/E) ratio for Lyell Immunopharma (LYEL) stock is 0 as of July 27, 2024.
Does Lyell Immunopharma stock pay dividends?
No, Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Lyell Immunopharma dividend payment date?
Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Lyell Immunopharma?
Lyell Immunopharma (LYEL) has a beta rating of -0.4. This means that it has an inverse relation to market volatility.
Buy or sell Lyell Immunopharma stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.